Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Junshi's PD-1 Candidate Approved for US Fast Track Review

publication date: Jan 25, 2021

Junshi Bio of Shanghai was granted US Fast Track status by the FDA for its anti-PD-1, toripalimab, to treat patients with advanced mucosal melanoma. The drug will be administered together with axitinib, a Pfizer VEGFR inhibitor, in a Phase III trial. In 2018, toripalimab was the first China-developed PD-1 therapy to be approved in China. The first approval was for second-line treatment of metastatic melanoma. Junshi is conducting more than thirty clinical trials of toripalimab globally for 15 indications. More details....

Stock Symbols: (HK: 1877; SHA: 688180)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here